Loading news...
Shell PLC's (LSE:SHEL, NYSE:SHEL) fourth-quarter 2025 update was slightly below expectations, according to analysts at Deutsche Bank and RBC Capital...
Shares in Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF) rose 7.4% to CHF 13.14 after the group struck a licensing deal worth up to $205 million plus...
Shell PLC (LSE:SHEL, NYSE:SHEL) issued an update to its fourth quarter outlook on Thursday, flagging to investors softer trading. In London, the share was...
Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF) has signed a licensing deal worth up to $205 million plus royalties for its Duchenne muscular dystrophy...
Press Release December 4, 2025 Shell plc Announces Final Results of Exchange Offers Shell plc (“Shell”) (LSE: SHEL) (NYSE: SHEL) (AEX: SHELL) today announces the final results of its previously announced offers to exchange (the “Exchange Offers” and each, an “Exchange Offer”) any and all validly tendered (and not validly withdrawn) and accepted notes of five series issued by Shell International Finance B.V. (“Shell International Finance” and such notes, the “Shell International Finance Notes”) and one series of notes issued by BG Energy Capital plc (“BGEC”) (such notes, the “BGEC Notes” and such BGEC Notes, together with the Shell International Finance Notes, the “Old Notes”) for a combination of cash and a corresponding series of new notes to be issued on a private placement basis by Shell Finance US Inc. (“Shell Finance US”) and fully and unconditionally guaranteed by Shell (the “New Notes”), as described in the Offering Memorandum dated November 3, 2025 (the “Offering Memorandum”).